The earnings call highlighted significant organic growth, profitability improvements, and strategic advancements in new markets, alongside effective cash and debt management. The main challenge was the impact of prior divestitures and foreign exchange losses.

Company Guidance

During the Bioventus Inc. Third Quarter 2025 Earnings Conference Call, the company reiterated its full-year guidance on all metrics, emphasizing robust third-quarter performance. The company reported a third-quarter revenue of $139 million, reflecting an 8% organic growth, with notable increases in key segments such as pain treatments and surgical solutions. Adjusted EBITDA rose by 13% to $27 million, with a margin expansion of over 200 basis points, and adjusted earnings per share surged by 200% to $0.15. Cash from operations nearly tripled from the previous year, contributing to a year-to-date increase of 88%. Bioventus remains on track to achieve a full-year adjusted EBITDA margin expansion of 100 basis points and aims for adjusted EPS between $0.64 to $0.68. The company highlighted strategic growth opportunities in its pain treatments business, particularly in peripheral nerve stimulation and platelet-rich plasma, projecting a 200 basis point boost in profitable growth for 2026.

Organic Revenue Growth

Third quarter revenue increased 8% on an organic basis, with above-market growth in all business segments, achieving mid-single-digit to low double-digit growth.

Adjusted EBITDA and Margin Expansion

Adjusted EBITDA increased by 13% with a margin expansion of over 200 basis points, demonstrating strong operational efficiencies.

Free Cash Flow Acceleration

Cash from operations nearly tripled in the third quarter compared to the previous year, with a cash conversion ratio of over 100%.

Peripheral Nerve Stimulation and PRP Development

Positive feedback received on the launch of StimTrial and TalisMann following FDA clearance and the new PRP system, Excel, with expectations of 200 basis points of profitable growth in 2026.

Debt Reduction

Debt decreased by $19 million during the quarter, with plans to reduce net leverage below 2.5x by year-end.

Bioventus (BVS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BVS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 17, 2026	2025 (Q4)	0.20 / -	0.15	―	―	―
Nov 04, 2025	2025 (Q3)	0.10 / 0.15	0.06	150.00% (+0.09)
Aug 06, 2025	2025 (Q2)	0.16 / 0.21	0.19	10.53% (+0.02)
May 06, 2025	2025 (Q1)	0.03 / 0.08	0.07	14.29% (<+0.01)
Mar 11, 2025	2024 (Q4)	0.08 / 0.15	0.07	114.29% (+0.08)
Nov 05, 2024	2024 (Q3)	0.02 / 0.06	0.05	20.00% (<+0.01)
Aug 06, 2024	2024 (Q2)	0.07 / 0.19	0.14	35.71% (+0.05)
May 07, 2024	2024 (Q1)	-0.07 / 0.07	-0.26	126.92% (+0.33)
Mar 12, 2024	2023 (Q4)	0.02 / 0.07	-0.06	216.67% (+0.13)
Nov 07, 2023	2023 (Q3)	-0.02 / 0.05	0.08	-37.50% (-0.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BVS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 04, 2025	$6.56	$7.55	+15.09%
Aug 06, 2025	$6.14	$7.29	+18.73%
May 06, 2025	$7.03	$6.20	-11.81%
Mar 11, 2025	$8.76	$10.80	+23.29%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Bioventus, Inc. (BVS) report earnings?

Bioventus, Inc. (BVS) is schdueled to report earning on Mar 17, 2026, After Close (Confirmed).

What is Bioventus, Inc. (BVS) earnings time?

Bioventus, Inc. (BVS) earnings time is at Mar 17, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BVS EPS forecast?

BVS EPS forecast for the fiscal quarter 2025 (Q4) is 0.2.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing